2015 GLOBAL OPPORTUNITIES IN ENDOVASCULAR MANAGEMENT OF AORTIC ANEURYSM DISEASE

200 Pages | 2015 Analysis | Forecasts Through 2019

OVERVIEW:
This report is focused on primary and ancillary technologies employed in endovascular aortic aneurysm repair (EVAR). Commercially introduced about two decades ago, less invasive EVAR techniques quickly emerged as the preferred treatment modality for life-threatening, rupture-prone abdominal and thoracic aortic aneurisms in the U.S. and as a viable alternative to highly invasive and risky surgery in Europe and other regions of the world. By the end of 2014, cumulative global EVAR device revenues exceeded $1.5 billion and are expected to approach $2.2 billion by 2019, reflecting increasing adoption of EVAR techniques as a substitute for surgery in barely penetrated emerging markets. The report also covers endovascular technologies used to address EVAR revisions that are required in up to one-third of treated AAA and TAA caseloads and which are necessitated by a still significant incidence of endoleaks and endograft failures. These revision technologies include proximal endograft anchoring-fixation devices, as well as specialty embolics for improved hemoisolation of aneurysmal sacs.

Epidemiological, procedure and market data are presented for four market geographies, including the United States, Major Europe (the five largest Western European States), Major Asia-Pacific (encompassing China, India and Japan), and Rest of the World nations. The report projections are based on detailed, clinical and econometric models for the years 2013 through 2019 that are intended to act as a working tool for clients of the report. They provide dynamic models of the clinical conditions driving product demand, the covered technologies' utilization patterns and revenue growth within the context of endovascular practices in the targeted regions, historic analogies of adoption of similar endovascular tools and techniques, priorities in local healthcare policies, and the availability of funding, among other factors.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

1. Overview of Aortic Aneurysm Etiology and Epidemiology

1.1 Aneurysms by Major Site
	1.1.1 Abdominal
		1.1.1.1	Infrarenal AAA
		1.1.1.2	Suprarenal AAA	
	1.1.2 Thoracic	
1.2 Causes, Risk Factors & Symptoms
1.3 Mortality & Morbidity
1.4 Treatment Options
	1.4.1 Open Surgery
	1.4.2 Endovascular Aneurysm Repair (EVAR) with Endografts
1.5 Incidence by Major Geography
	
2. Endograft Technologies

2.1 Abdominal Aortic Endografts
	2.1.1 Indications
	2.1.2 Configurations
	2.1.3 Clinical Experience
	2.1.4 Products & Suppliers
2.2 Thoracic Aortic Endografts
	2.2.1 Indications
	2.2.2 Configurations
	2.2.3 Clinical Experience
	2.2.4 Products & Suppliers

3. Global Markets for Aortic Endografts
 	
3.1 Abdominal Aortic Endografts
	3.1.1 Procedures by Major Geography
	3.1.2 Market Forecast by Major Geography
	3.1.3 Competitive Analysis
3.2 Thoracic Aortic Endografts
	3.2.1 Procedures by Major Geography
	3.2.2 Market Forecast by Major Geography
	3.2.3 Competitive Analysis
		
4. Company Profiles
   
4.1 Cook Medical (Cook Group)
4.2 Cordis (Johnson & Johnson)
4.3 Duke Vascular
4.4 Endologix
4.5 W.L. Gore
4.6 Lombard Medical
4.7 Medtronic/Covidien
4.8 MicroPort Medical
4.9 Nano Endoluminal
4.10 Terumo Vascutek
4.11 TriVascular

5. Major Country/Regional Healthcare Profiles

5.1 United States
5.2 Major Europe
	5.2.1 France
	5.2.2 Germany
	5.2.3 Italy
	5.2.4 Spain
	5.2.5 United Kingdom
5.3 Major Asia-Pacific
	5.3.1 China
	5.3.2 India
	5.3.3 Japan


COMPANIES COVERED:

  1. Cook Medical (Cook Group)
  2. Cordis (Johnson & Johnson)
  3. Duke Vascular
  4. Endologix
  5. W.L. Gore
  6. Lombard Medical
  7. Medtronic/Covidien
  8. MicroPort Medical
  9. Nano Endoluminal
  10. Terumo Vascutek
  11. TriVascular
Contact Us

Need help finding medtech research? Let us help you!